Headlines on the fledgling marijuana industry.
|ACB||Aurora Cannabis Inc.||
|CRON||Cronos Group Inc.||
|WEED||Canopy Growth Corp.||
|TLRY||Tilray Brands Inc. Cl 2||
More from Cannabis Watch
Analyst slashes revenue outlook for Trulieve, Curaleaf, Canopy, Cronos as cannabis business takes a hit
Owen Bennett of Jefferies cuts estimates on major cannabis names as the economic slowdown and oversupply in some markets bite into projections.
Trulieve trims view as inflation hits cannabis prospects
While parts of Trulieve's business held steady, inflation and lower revenue in its wholesale unit weighed on results.
Curaleaf CEO sees cannabis as recession resistant, but stock falls after wider loss
Curaleaf stock slides into the red after the company matches estimates for a loss and beats its revenue target, but its wholesale business faces price pressure
Tilray expected to post a quarterly loss with market share losses in Canada and forex headwinds
Cannabis company is seen losing 8 cents a share amid tough market conditions in Canada, but one analyst eyes more traction in recent weeks.
Cannabis activist says convictions amount to modern ‘scarlet letter’ in Senate hearing on marijuana decriminalization
Sen. Durbin hails ex-cannabis convict Weldon Angelos as a "legend," but Angelos still can't shake the fallout even with a presidential pardon.
More second-chance drug tests for DOT-regulated drivers signal shift away from zero-tolerance policies
Employers allow a path back to work instead of firing for drug test infractions, but Feds warn cannabis remains illegal despite state rules.
Cannabis SPAC Choice Consolidation returns money to shareholders
Subhead: CEO says liquidation a logical choice given market conditions
Analysts see no lift for downbeat cannabis stocks from Chuck Schumer’s bill
Schumer's Cannabis Administration and Opportunity Act (CAOA) draws praise and criticism, but a separate safe banking measure may be a frontrunner for passage.
Chuck Schumer leads wide-ranging Senate bill to remove cannabis from federal list of controlled substances
Senate Majority Leader Schumer launches Cannabis Administration and Opportunity Act (CAOA) with Senators Ron Wyden and Cory Booker.
Short positions ease back on cannabis stocks, but shares remain deeply in the red
Short positions in cannabis stocks have fallen this year, but stock price losses in the sector pile up on lack of U.S. legalization and weak Canadian markets.
Cannabis debt holds up better than stocks in brutal 2022
Shares of cannabis stock have lost half their value in the first half of 2022, but bonds from some of the larger multi-state operators maintain some strength
FDA stalled on CBD for now: Analyst
FDA expresses interest in more studies of CBD but no real action is expected without a push from Congress, according to Cowen analyst.
Cannabis banking measure gets fresh look on Capitol Hill
Lawmakers met to consider combining the SAFE Banking measure to open up the banking system with other social equity measures.
Cannabis company Long Play shops for brands to add to Willie Nelson, Tom Petty portfolio
Cannabis company looks for opportunities where music and cannabis meet as it looks to grow pot's appeal to mainstream consumers.
Canopy Growth shares slide on wider-than-expected loss
Constellation-backed cannabis company Canopy Growth posts narrower loss but faces price compression as it works to maintain its market share in premium flower.
Two cannabis CEOs praise letter supporting SAFE Banking from U.S. senators
Trulieve and Ascend Wellness CEOs say measure will help smaller players succeed in the business and improve security at cannabis stores.
Here’s why Curaleaf looks past headwinds and sticks to 2022 revenue view
Boris Jordan says cannabis company remains on track to generate revenue of $1.4 billion to $1.5 billion in 2022 despite a tough Q1.
Acreage sees cannabis business sprouting in the Northeast
CFO says the company looks forward to further growth in New Jersey, New York and Connecticut as adult use sales come on line
Green Thumb Industries CEO eyes cash flow in vein of Warren Buffett
CEO Ben Kovler highlights cannabis company's cash generation as an overlooked attribute in its latest earnings results.
Stifel cuts cannabis industry view as analysts weigh Tilray
Stifel reduces 2022 U.S. cannabis sales view by $1.4 billion and cuts earnings targets on Scotts Miracle-Gro and Hydrofarm; Tilray in spotlight.